HR Execs on the Move

RayzeBio

www.rayzebio.com

 
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.rayzebio.com
  • 5505 Morehouse Drive Suite 300
    San Diego, CA USA 92121
  • Phone: 858.257.3449

Executives

Name Title Contact Details
Arvind Kush
Chief Financial Officer Profile
Ken Song
President and Chief Executive Officer Profile

Similar Companies

Biosound Inc

Biosound Inc is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Breonics

Breonics is a Otisville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Applied Genomics

Applied Genomics is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MicroBiotix

MicroBiotix is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vivodyne

Vivodyne accelerates the successful discovery, design, and development of human therapeutics through the convergence of novel biology, robotics, and AI. Our platform enables customers to massively de-risk drug candidates by testing them against functional, lab-grown, human organs and multi-organ systems. We conduct preclinical discovery and clinical development campaigns to generate new therapeutic strategies from these proprietary, physiologically-realistic organs at unprecedented scale, speed, and quality through automation and machine learning. We`re financially backed by some of the most selective and successful venture funds, and several “Top 10” global pharmaceutical innovators have already partnered with us to expand, strengthen, and accelerate their therapeutic pipelines.